SARC024: A blanket protocol to study oral regorafenib in patients with refractory
liposarcoma, osteogenic sarcoma, and Ewing/Ewing–like sarcomas
The purpose of this study is to compare the effects good and/or bad of the study drug, regorafenib, versus placebo on your liposarcoma or bone sarcoma. Another purpose is to study the effects of the study drug on your Ewing-sarcoma to determine the effects, good and/or bad.
Liposarcoma, Osteogenic sarcoma (bone sarcoma) and Ewing / Ewing- like sarcoma
Participants 18 and older with liposarcoma, bone sarcoma, or Ewing sarcoma who have had at least one prior form of systemic treatment for their cancer. Screening labs and imaging studies will be done to confirm eligibility.
18 - 120
Healthy Volunteers Needed
Duration of Participation
Participants will be in the study for as long as they are seeing clinical benefit.
Sarcoma Alliance for Research through Collaboration (SARC)